SCHEMBL2536307

SCHEMBL2536307

COCCc1nn(Cc2ccc(OC)cc2)cc1-c1csc(Nc2nccc(C)n2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.42
MEN1 O00255 8/20 0.42
KMT2A Q03164 8/20 0.42
SMN1; SMN2 Q16637 6/20 0.42
ALDH1A1 P00352 6/20 0.42
KDM4E B2RXH2 1/20 0.42
AMY1A P0DUB6 1/20 0.39
WNT3A P56704 1/20 0.39
NPC1 O15118 6/20 0.38
RAB9A P51151 6/20 0.38
VCP P55072 1/20 0.37
KDM1A O60341 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
HDAC5 Q9UQL6 1/20 0.37
NFKB1 P19838 4/20 0.36
NFKB2 Q00653 4/20 0.36
RELA Q04206 4/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL366183 0.86 MEN1 (0.40) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL369474 0.84 WNT3A (0.39) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL2512904 0.83 RAB9A (0.44) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL370432 0.81 RAB9A (0.45) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL369359 0.80 KMT2A (0.35) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL370330 0.78 WNT3A (0.37) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL369911 0.78 WNT3A (0.37) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL370879 0.77 MEN1 (0.44) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL369447 0.76 WNT3A (0.42) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL3354435 0.76 NPC1 (0.58) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9073907-B2 Thiazoles derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors ADDEX PHARMA S.A. (CH) 2015-07-07 US disclosed
EP-2376486-B1 NOVEL THIAZOLES DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMACEUTICALS SA (CH) 2013-11-06 EP disclosed
US-20110257179-A1 NOVEL THIAZOLES DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA SA (CH) 2011-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257179-A1 NOVEL THIAZOLES DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM2, GRM1 MAPT 1013/4885MEN1 3967/4885KMT2A 2333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.